Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
GEMINI-NSCLC: NSCLC Biomarker Study
NCT05236114 · View on ClinicalTrials.gov ↗
Study Summary
GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.
Conditions Studied
Interventions
- OTHER Observation
Study Locations (20)
Illinois
- Southern Illinois Hospital Services — Carterville
- Cancer Care Specialists of Illinois — Decatur
- Northwestern University — Evanston
- Hope and Healing Cancer Services — Hinsdale
- OSF Saint Anthony Medical Center — Rockford
California
- MemorialCare — Fountain Valley
- Cancer and Blood Specialty Clinic — Los Alamitos
- UCLA — Los Angeles
Florida
- Clermont Oncology Center — Clermont
- Woodlands Medical Specialists — Pensacola
Georgia
- Morehouse School of Medicine (MSM) — Atlanta
- Piedmont Healthcare — Atlanta
Maryland
- University of Maryland — Baltimore
- Johns Hopkins University — Baltimore
Alabama
- Alabama Oncology — Birmingham
Arkansas
- Mercy Clinic Oncology - Fort Smith — Fort Smith
Connecticut
- Eastern CT and Hematology and Oncology Associates — Norwich
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2022-06-22 |
| Est. Completion | 2029-06 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05236114
The ClinicalTrials.gov registry entry for NCT05236114 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tempus AI, which has 12 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention — of which Observation is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05236114 reports 20 study locations spanning 11 distinct geographic areas — top geographies include Illinois, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05236114 about?
NCT05236114 is a clinical study titled "GEMINI-NSCLC: NSCLC Biomarker Study". GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecula...
What is the current status of trial NCT05236114?
This trial is currently recruiting. The enrollment target is 1,200 participants. The study started on 2022-06-22. Estimated completion is 2029-06.
What conditions does trial NCT05236114 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05236114?
The interventions under investigation include: Observation (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05236114?
This trial is sponsored by Tempus AI, which has 12 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05236114 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.